Loading stocks --
Market News
English اردو

Citi Pharma FY26 net profit softens 11% to Rs790m

CPHL Citi Pharma Ltd.
Rs. 62.18 -0.27%
Stock ImpactNegative

Citi Pharma Limited (PSX: CPHL) reported an 11% decline in its consolidated net profit for the fiscal year ended June 30, 2026, recording Rs790.33m compared to Rs892.04m in the preceding year.

Reflecting this bottom-line compression, basic and diluted earnings per share (EPS) for the year fell to Rs3.46, down from Rs3.90 in FY25. The primary factors weighing on final earnings were rising marketing overheads, elevated financial charges, and higher operating expenses, which offset a 7% top-line revenue expansion.

DescriptionFY26 (Rs)FY25 (Rs)Change %
Sales - net14,075,802,87113,153,521,8577.0%
Gross profit2,472,941,1532,017,608,31822.6%
Profit for the year790,333,542892,038,934-11.4%
Earnings per share (Rs)3.463.90-11.3%

Read the full story on the original publisher’s website.

Open original article